NASDAQ · Financial Statements
Gemini Therapeutics, Inc. (GMTX) Financial Statements
$1.35
NASDAQ: GMTX
Market Cap $25.49M
Overview Financials Dividend Gemini Therapeutics, Inc. most recently net profit of $-212.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue — — — — — Operating Profit $-31.0M $-47.0M $-91.0M $-130.0M $-236.0M Net Profit $-36.0M $-47.0M $-76.0M $-109.0M $-212.0M EPS $-40.95 $-45.05 $-3.42 $-3.96 $-6.01 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $92.0M $200.0M $368.0M $497.0M $807.0M Total Liabilities $15.0M $24.0M $23.0M $53.0M $67.0M Cash $88.0M $195.0M $360.0M $192.0M $91.0M Borrowings $14.0M $14.0M — $28.0M $29.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-28.0M $-42.0M $-73.0M $-94.0M $-180.0M Investing Cash Flow $0 $0 $0 $-292.0M $-394.0M Financing Cash Flow $90.0M $149.0M $239.0M $218.0M $473.0M Net Cash Flow $62.0M $107.0M $166.0M $-168.0M $-101.0M Free Cash Flow $-28.0M $-42.0M $-74.0M $-94.0M $-181.0M
Valuation & Return Ratios
Metric Value PEG Ratio — EV / EBITDA — FCF Yield -710.03% Quick Ratio 21.73 Interest Coverage -118.00 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock